Clinical Trial Update: IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating Ivonescimab in metastatic endocrine-refractory HR-positive/HER2-negative breast cancer and metastatic triple-negative invas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Invasive Lobular Carcinoma

Drugs mentioned

• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Endocrine Refractory, Triple Negative Invasive Lobular Carcinoma | Phase 2 | Status: RECRUITING